Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) | European Psychiatry | Cambridge Core (original) (raw)

Abstract

People with severe mental illnesses, such as schizophrenia, depression or bipolar disorder, have worse physical health and reduced life expectancy compared to the general population. The excess cardiovascular mortality associated with schizophrenia and bipolar disorder is attributed in part to an increased risk of the modifiable coronary heart disease risk factors; obesity, smoking, diabetes, hypertension and dyslipidaemia. Antipsychotic medication and possibly other psychotropic medication like antidepressants can induce weight gain or worsen other metabolic cardiovascular risk factors. Patients may have limited access to general healthcare with less opportunity for cardiovascular risk screening and prevention than would be expected in a non-psychiatric population. The European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) published this statement with the aim of improving the care of patients suffering from severe mental illness. The intention is to initiate cooperation and shared care between the different healthcare professionals and to increase the awareness of psychiatrists and primary care physicians caring for patients with severe mental illness to screen and treat cardiovascular risk factors and diabetes.

References

Allison, D.B.Mentore, J.L.Heo, M.Chandler, L.P.Cappelleri, J.C.Infante, M.C.et al.Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686–1696Google Scholar PubMed

Allison, D.B.Newcomer, J.W.Dunn, A.L.Blumenthal, J.A.Fabricatore, A.N.Daumit, G.L.et al.Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med 2009;36(4):341–350CrossRef Google Scholar PubMed

Álvarez-Jiménez, M.Hetrick, S.González-Blanch, C.Gleeson, J.McGorry, P.Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008;193:101–107CrossRef Google Scholar PubMed

American Association of Clinical Endocrinologists 2007. Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus. AACE Diabetes Mellitus Guidelines. Endocr Pract 2007;13(Suppl. 1):3–68.Google Scholar

American Diabetes Association Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596–601CrossRef Google Scholar

American Diabetes Association Standards of medical care in diabetes - 2009. Diabetes Care 2009;32(Suppl. 1):S13–S61CrossRef Google Scholar

American Diabetes Association Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2009;32(Suppl. 1):S63–S67Google Scholar

Angst, F.Stassen, H.H.Clayton, P.J.Angst, J.Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002;68(2-3):167–181CrossRef Google Scholar PubMed

Arango, C.Bobes, J.Aranda, P.Carmena, R.Garcia-Garcia, M.Rejas, J.et al.A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. Schizophr Res 2008;104(1-3):1–12CrossRef Google Scholar PubMed

Barnett, A.H.Mackin, P.Chaudhry, I.Farooqi, A.Gadsby, R.Heald, A.et al.Minimising metabolic and cardiovascular risk in schizophrenia. J Psychopharmacol 2007;21(4):357–373CrossRef Google Scholar

Bech, P.Vendsborg, P.J.Rafaelson, O.J.Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine. Acta Psychiatr Scand 1976;53:70–81CrossRef Google Scholar PubMed

Berken, G.H.Weinstein, D.O.Stern, W.C.Weight gain: a side effect of tricyclic antidepressants. J Affect Disord 1984;7:133–138CrossRef Google Scholar PubMed

Bjorntorp, P.Stress and cardiovascular disease. Acta Physiol Scand Suppl 1997;640:144–148Google Scholar PubMed

Bobes, J.Arango, C.Aranda, P.Carmena, R.Garcia-Garcia, M.Rejas, J.et al.Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007;90(1-3):162–173CrossRef Google Scholar PubMed

Brown, A.D.Barton, D.A.Lambert, G.W.Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. CNS Drugs 2009;23(7):583–602CrossRef Google Scholar PubMed

Brown, L.C.Majumdar, S.R.Newman, S.C.Johnson, J.A.History of depression increases risk of type 2 diabetes in younger adults. Diabetes Care 2005;28:1063–1067CrossRef Google Scholar PubMed

Brown, S.Inskip, H.Barraclough, B.Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212–217CrossRef Google Scholar PubMed

Bruggeman, R.Schorr, S.Van der Elst, K.Postma, M.Taxis, K.Cost-effectiveness of screening for diabetes in a cohort of patients with schizophrenia. Schizophr Res 2008;102(1-3):161–162CrossRef Google Scholar

Buckley, P.F.Miller, D.D.Singer, B.Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005;79:281–288CrossRef Google Scholar PubMed

Bushe, C.J.Leonard, B.E.Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry 2007;68(11):1682–1690CrossRef Google Scholar PubMed

Cahn, W.Ramlal, D.Bruggeman, R.de Haan, L.Scheepers, F.E.van Soest, M.M.et al.Prevention and treatment of somatic complications arising from the use of antipsychotics. Tijdschr Psychiatr 2008;50(9):579–591Google Scholar PubMed

Canadian Diabetes Association Clinical Practice Guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl. 1):S1–S20Google Scholar

Capasso, R.M.Lineberry, T.W.Bostwick, J.M.Decker, P.A.St Sauver, J.Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950-2005. Schizophr Res 2008;98(1-3):287–294CrossRef Google Scholar PubMed

Carnethon, M.R.Biggs, M.L.Barzilay, J.I.Smith, N.L.Vaccarino, V.Bertoni, A.G.et al.Longitudinal Association Between Depressive Symptoms and Incident Type 2 Diabetes Mellitus in Older Adults. The Cardiovascular Health Study. Arch Intern Med 2007;167:801–808CrossRef Google Scholar PubMed

Casey, D.E.Haupt, D.W.Newcomer, J.W.Henderson, D.C.Sernyak, M.J.Davidson, M.et al.Antipsychotic-Induced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients With Schizophrenia. J Clin Psychiatry 2004;65(Suppl. 7):4–18Google Scholar PubMed

Cassidy, F.Ahearn, E.Carroll, B.J.Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999;156:1417–1420Google Scholar PubMed

Chrousos, G.P.The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuroendocrine and target tissue-related causes. Int J Obes 2000;24:S50–55CrossRef Google Scholar PubMed

Citrome, L.Risk-Benefit Analysis of Available Treatments for Schizophrenia. Psychiatric Times 2007;1:27–30Google Scholar

Citrome, L.Holt, R.I.G.Zachry, W.M.Clewell, J.D.Orth, P.A.Karagianis, J.L.et al.Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007;41:1593–1603CrossRef Google Scholar PubMed

Citrome, L.Yeomans, D.Do guidelines for severe mental illness promote physical health and well-being?. J Psychopharmacol 2005;19(6):102–109CrossRef Google Scholar PubMed

Cohen, D.Huinink, S.Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry. CNS Drugs 2007;21(12):1035–1038CrossRef Google Scholar PubMed

Cohen, D.Stolk, R.P.Grobbee, D.E.Gispen-de Wied, C.C.Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 2006;29(4):786–791CrossRef Google Scholar PubMed

Cohn, T.A.Sernyak, M.J.Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006;51:492–501CrossRef Google Scholar PubMed

Colton, C.W.Manderscheid, R.W.Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006;3:A42Google Scholar PubMed

Correll, C.U.Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008;69(Suppl. 4):26–36Google Scholar PubMed

Correll, C.U.Balancing efficacy and safety in the treatment with antipsychotics. CNS Spectr 2007;12(Suppl. 17):12–20CrossRef Google Scholar PubMed

Correll, C.U.Frederickson, A.M.Kane, J.M.Manu, P.Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008;10:788–797CrossRef Google Scholar PubMed

Correll, C.U.Frederickson, A.M.Kane, J.M.Manu, P.Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006;67(4):575–583CrossRef Google Scholar PubMed

Daniels, S.R.Greer, F.R.the Committee on Nutrition Lipid Screening and Cardiovascular Health in Childhood. Pediatrics 2008;122:198–208CrossRef Google Scholar PubMed

Daumit, G.L.Goff, D.C.Meyer, J.M.Davis, V.G.Nasrallah, H.A.McEvoy, J.P.et al.Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008;105:175–187CrossRef Google Scholar PubMed

De Hert, M.van Eyck, D.De Nayer, A.Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006;21(Suppl. 2):11–15CrossRef Google Scholar PubMed

De Hert, M.van Winkel, R.Van Eyck, D.Hanssens, L.Wampers, M.Scheen, A.et al.Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2006;2:14 doi: 10.1186/1745-0179-2-14.online.CrossRef Google Scholar PubMed

De Hert, M.Kalnicka, D.van Winkel, R.M.Hanssens, L.Van Eyck, D.Wampers, M.et al.Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2006;67(12):1889–1896CrossRef Google Scholar PubMed

De Hert, M.Falissard, B.Mauri, M.Shaw, K.Wetterling, T.Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: The METEOR Study. Eur Neuropsychopharmacol 2008;18(Suppl. 4):S444CrossRef Google Scholar

De Hert, M.Schreurs, V.Sweers, K.Van Eyck, D.Hanssens, L.Šinko, S.et al.Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008;101(1-3):295–303CrossRef Google Scholar PubMed

De Hert, M.Schreurs, V.Vancampfort, D.van Winkel, R.Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009;8(1):15–22CrossRef Google Scholar PubMed

De Nayer, A.De Hert, M.Scheen, A.Van Gaal, L.Peuskens, J.Belgian consensus on metabolic problems associated with atypical antipsychotics. Int J Clin Pract 2005;9:130–137CrossRef Google Scholar PubMed

Druss, B.G.Improving medical care for persons with serious mental illness: challenges and solutions. J Clin Psych 2007;68(Suppl. 4):40–44Google Scholar PubMed

Eaton, W.W.Armenian, H.Gallo, J.Pratt, L.Ford, D.E.Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care 1996;19(10):1097–1102CrossRef Google Scholar PubMed

Falkai, P.Wobrock, T.Lieberman, J.Glenthoj, B.Gattaz, W.F.Möller, H.J.et al.Guidelines for Biological Treatment of Schizophrenia. Part 1: Acute treatment of Schizophrenia. World J Biol Psychiatry 2005;6(3):132–191CrossRef Google Scholar PubMed

Farouhi, N.G.Balkau, B.Borch-Johnsen, K.Dekker, J.Glumer, C.Qiao, Q.et al.The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia 2006;49:822–827Google Scholar

Faulkner, G.Soundy, A.A.Lloyd, K.Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatrica Scandinavica 2003;108:324–332CrossRef Google Scholar PubMed

Faulkner, G.Cohn, T.A.Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 2006;51(8):502–511CrossRef Google Scholar PubMed

Faulkner, G.Cohn, T.Remington, G.Interventions to reduce weight gain in schizophrenia. Schizophr Bull 2007;33(3):654–656CrossRef Google Scholar

Faulkner, G.Taylor, A.Munro, S.Selby, P.Gee, C.The acceptability of physical activity programming within a smoking cessation service for individuals with severe mental illness. Patient Educ Couns 2007;66(1):123–126CrossRef Google Scholar PubMed

Fenton, W.S.Stover, E.S.Mood disorders: cardiovascular and diabetes comorbidity. Curr Opin Psychiatry 2006;19:421–427CrossRef Google Scholar PubMed

Fleischhacker, W.W.Cetkovich-Bakmas, M.De Hert, M.Hennekens, C.Lambert, M.Leucht, S.et al.Cormorbid somatic illnesses in patients with severe mental disorders: clinical, policy and research challenges. J Clin Psychiatry 2008;69:514–519CrossRef Google Scholar

Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prevent Rehabil 2007;14(Suppl. 2):E1–E40Google Scholar

Goff, D.C.Sullivan, L.M.McEvoy, J.P.Meyer, J.Nasrallah, H.Daumit, G.et al.A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005;80(1):45–53CrossRef Google Scholar PubMed

Haddad, P.M.Sharma, S.G.Adverse effects of atypical antipsychotics; Differential Risk and Clinical Implications. CNS Drugs 2007;21:911–936CrossRef Google Scholar PubMed

Hanssens, L.De Hert, M.Kalnicka, D.van Winkel, R.Wampers, M.Van Eyck, D.et al.Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol 2007;22:43–49Google Scholar PubMed

Haupt, D.W.Rosenblatt, L.C.Kim, E.Baker, R.A.Whitehead, R.Newcomer, J.W.Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009;166(3):345–353CrossRef Google Scholar PubMed

Henderson, D.C.Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005;66(Suppl. 6):11–20Google Scholar PubMed

Hennekens, C.H.Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;151(3):598–603Google Scholar

Hill Golden, S.Lazo, M.Carnethon, M.Bertoni, A.G.Schreiner, P.J.Dieze Roux, A.et al.Examining a Bidirectional Association Between Depressive Symptoms and Diabetes. JAMA 2008;299(23):2751–2759CrossRef Google Scholar

Holt, R.I.G.Bushe, C.Citrome, L.Diabetes and schizophrenia 2005: are we any closer to understanding the link?. J Psychopharmacol 2005;19(6):56–65CrossRef Google Scholar PubMed

Holt, R.I.G.Severe mental illness, antipsychotic drugs and the metabolic syndrome. Br J Diab Vasc Disease 2006;6(5):199–204CrossRef Google Scholar

Holt, R.I.G.Peveler, R.C.Antipsychotic drugs and diabetes - an application of the Austin Bradford Hill criteria. Diabetologia 2006;49(7):1467–1476CrossRef Google Scholar PubMed

Holt, R.Peveler, R.Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab 2009;11(7):665–679CrossRef Google Scholar PubMed

Kahl, K.G.Bester, M.Greggersen, W.Rudolf, S.Dibbelt, L.Stoeckelhuber, B.M.et al.Visceral fat disposition and insulin sensitivity in depressed women with and without borderline personality disorder. Psychosom Med 2005;67:407–412CrossRef Google Scholar

Kahn, R.S.Fleischhacker, W.W.Boter, H.Davidson, M.Vergouwe, Y.Keet, I.et al.Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085–1097CrossRef Google Scholar PubMed

Kinder, L.S.Carnethon, M.R.Palaniappan, L.P.King, A.C.Fortmann, S.P.Depression and the metabolic syndrome in young adults: Findings from the Third National Health and nutrition Examination Survey. Psychosom Med 2004;66:316–322CrossRef Google Scholar PubMed

Kinon, B.J.Kaiser, C.J.Ahmed, S.Roteli, M.Kolloack-Walker, S.Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005;25(3):255–258CrossRef Google Scholar PubMed

Kissebah, A.H.Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease?. Diab Res Clin Pract 1996;30:25–30CrossRef Google Scholar

Knowler, W.C.Barrett-Connor, E.Fowler, S.E.Hamman, R.F.Lachin, J.M.et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393–403Google Scholar PubMed

Kryzhanovskaya, L.A.Robertson-Plouch, C.K.Xu, W.Carlson, J.L.Merida, K.M.Dittmann, R.W.The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry 2009;70(2):247–258CrossRef Google Scholar PubMed

Kumra, S.Oberstar, J.V.Sikich, L.Findling, R.McClellan, J.Vinogradoc, S.et al.Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia. Schizophr Bull 2008;34:60–71CrossRef Google Scholar PubMed

Lamberti, J.S.Crilly, J.F.Maharaj, K.Olson, D.Wiener, K.Dvorin, S.et al.Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 2004;65:702–706CrossRef Google Scholar PubMed

Laursen, T.M.Munk-Olsen, T.Agerbo, E.Gasse, C.Mortensen, P.B.Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 2009;66(7):713–720CrossRef Google Scholar PubMed

Lawrence, D.M.Holman, C.D.Jablensky, A.V.Hobbs, M.S.Death rate from ischemic heart disease in Western Australian psychiatric patients 1980-1998. Br J Psychiatry 2003;182:31–36CrossRef Google Scholar PubMed

Leucht, S.Burkard, T.Henderson, J.Maj, M.Sartorius, N.Physical illness and schizophrenia. Acta Psychiatr Scand 2007;116(5):317–333CrossRef Google Scholar

Leucht, S.Corves, C.Arbter, D.Engel, R.R.Li, C.Davis, J.M.Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31–41CrossRef Google Scholar PubMed

Lieberman, J.A.Stroup, T.S.McEvoy, J.P.Swartz, M.S.Rosenheck, R.A.Perkins, D.O.et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209–1223CrossRef Google Scholar PubMed

Mackin, P.Bishop, D.Watkinson, H.A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 2007;25:7–28Google Scholar

Maina, G.Salvi, V.Vitalucci, A.D’Ambrosio, V.Bogetto, F.Prevalence and correlates of overweight in drug-naive patients with bipolar disorders. J Affect Disord 2008;110:149–155CrossRef Google Scholar

Mancia, G.De Backer, G.Dominiczak, A.Cifkova, R.Fagard, R.Germono, G.et al.Guidelines for the management of arterial hypertension. Eur Heart J 2007;28:1462–1536Google Scholar PubMed

Marder, S.R.Essock, S.M.Miller, A.L.Buchanan, R.W.Casey, D.E.Davis, J.M.et al.Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334–1349CrossRef Google Scholar PubMed

McIntyre, R.S.Konarski, J.Z.Misener, V.L.Kennedy, S.H.Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005;17(2):83–93CrossRef Google Scholar PubMed

McIntyre, R.S.Sozcynska, J.K.Konarski, J.Z.Kennedy, S.H.The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006;5:157–168CrossRef Google Scholar PubMed

Meyer, J.M.Davis, V.G.Goff, D.C.McEvoy, J.Nasrallah, H.Davis, S.et al.Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophr Res 2008;101(1-3):273–286CrossRef Google Scholar PubMed

Meyer, J.M.Stahl, S.M.The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119(1):4–14CrossRef Google Scholar

Miller, L.J.Management of Atypical Antipsychotic Drug–Induced Weight Gain: Focus on Metformin Pharmacotherapy 2009;29(6):725–735Google Scholar

Nasrallah, H.A.Meyer, J.M.Goff, D.C.McEvoy, J.P.Davis, S.M.Stroup, T.S.et al.Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86(1-3):15–22CrossRef Google Scholar PubMed

Nasrallah, H.A.Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13:27–35CrossRef Google Scholar PubMed

Nathan, D.M.Davidson, M.B.DeFronzo, R.A.Heine, R.J.Henry, R.R.et al.Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753–759CrossRef Google Scholar

Newcomer, J.W.Nasrallah, H.A.Loebel, A.D.The atypical antipsychotic therapy and metabolic issues national survey. J Clin Psychopharmacol 2004;24:1–6CrossRef Google Scholar PubMed

Newcomer, J.W.Second-Generation (Atypical) Antipsychotics and Metabolic Effects. A Comprehensive Literature Review. CNS Drugs 2005;19(Suppl. 1):1–93CrossRef Google Scholar PubMed

Newcomer, J.W.Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(Suppl. 4):8–13Google Scholar PubMed

NICE. Schizophrenia Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. 2008; online:http://www.nice.org.uk/guidance/index.jsp?action=download&o=42139 (site consulted on 1st July 2009).Google Scholar

Nicol, G.Haupt, D.Flavin, K.Schweiger, J.Hessler, M.Hessler, E.et al.Preliminary results of the MEAC study: metabolic effects of antipsychotics in children. Schizophr Bull 2009;35(Suppl. 1):32Google Scholar

Osborn, D.P.Levy, G.Nazareth, I.Petersen, I.Islam, A.King, M.B.Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry 2007;64(2):242–249CrossRef Google Scholar PubMed

Osborn, D.P.Wright, C.A.Levy, G.King, M.B.Deo, R.Nazareth, I.Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and meta-analysis. BMC Psychiatry 2008;8:84 25CrossRef Google Scholar

Ösby, U.Correia, N.Brandt, L.Ekbom, A.Sparen, P.Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45(1-2):21–28CrossRef Google Scholar PubMed

Ösby, U.Correia, N.Brandt, L.Ekbom, A.Sparen, P.Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study. BMJ 2000;321(7259):483–484CrossRef Google Scholar PubMed

Peiris, A.N.Sothmann, M.S.Hoffmana, R.G.Hennes, M.I.Wilson, C.R.Adiposity, fat distribution, and cardiovascular risk. Ann Int Med 1989;110:867–872CrossRef Google Scholar PubMed

Pratt, L.Ford, D.Crum, R.Armenian, H.Gallo, J.Eaton, W.Depression, Psychotropic Medication, and Risk of Myocardial Infarction. Circulation 1996;94:3123–3129CrossRef Google Scholar PubMed

Ray, W.A.Chung, C.P.Murray, K.T.Hall, K.Stein, C.M.Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360(3):225–235CrossRef Google Scholar PubMed

Rozanski, A.Blumenthal, J.A.Kaplan, J.Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99:2192–2217CrossRef Google Scholar PubMed

Rubin, R.R.Ma, Y.Marrero, D.G.Peyrot, M.Barret-Conner, E.L.Kahn, S.E.et al.Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008;31:420–426CrossRef Google Scholar PubMed

Saha, S.Chant, D.McGrath, J.A Systematic Review of Mortality in Schizophrenia. Arch Gen Psychiatry 2007;64:1123–1131CrossRef Google Scholar

Sahota, D.P.Knowler, W.Looker, H.Depression, diabetes and glycemic control in an American Indian Community. J Clin Psychiatry 2008;69(5):800–809CrossRef Google Scholar

Sáiz Ruiz, J.Bobes García, J.Vallejo Ruiloba, J.Giner Ubago, J.García-Portilla González, M.P.Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry. Actas Esp Psiquiatr 2008;36(5):251–264Google Scholar PubMed

Scheen, A.J.De Hert, M.A.Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007;33:169–175CrossRef Google Scholar PubMed

Scheen, A.van Winkel, R.De Hert, M.Traitement neuroleptique et troubles metabolic. Med Mal Metabol 2008;2(6):593–599Google Scholar

Simon, V.van Winkel, R.De Hert, M.Are weight gain and metabolic side-effects of atypical antipsychotics dose-dependent? A Literature review. J Clin Psychiatry 2009;70(7):1041–1050CrossRef Google Scholar PubMed

Smith, M.Hokins, D.Peveler, R.Holt, R.Woodward, M.Ismail, K.First- versus second generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008;192(6):406–411CrossRef Google Scholar

Smith, R.C.Lindenmayer, J.P.Davis, J.M.Cornwell, J.Noth, K.Gupta, S.et al.Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009;110(1-3):149–155CrossRef Google Scholar PubMed

Stahl, S.M.Mignon, L.Meyer, J.M.Which comes first: atypical antipsychotic treatment or cardiometabolic risk?. Acta Psychiatr Scand 2009;119(3):171–179CrossRef Google Scholar PubMed

Stroup, T.S.Lieberman, J.A.McEvoy, J.P.Swartz, M.S.Davis, S.M.Rosenheck, R.A.et al.Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163(4):611–622CrossRef Google Scholar PubMed

Stunkard, A.J.Myles, M.S.Allison, K.C.Depression and obesity. Biol Psychiatry 2003;54:330–337Google Scholar PubMed

Surtees, P.G.Wainwright, N.W.J.Luben, R.N.Wareham, N.J.Bingham, S.A.Khaw, S.Depression and ischemic Heart Disease Mortality: Evidence From the EPIC-Norfolk United Kingdom Prospective Cohort Study. Am J Psychiatry 2008;165:515–523CrossRef Google Scholar PubMed

Taxis, K.Schorr, S.Fouchier, M.Slooff, C.Bruggeman, R.Is it appropriate to use cardiovascular risk scores in patients with psychotic disorders?. Schizophr Res 2008;102(1-3):169CrossRef Google Scholar

Thakore, J.H.Richards, P.J.Reznek, R.H.Martin, A.Dinan, T.G.Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computer tomography. Biol Psychiatry 1997;41:1140–1142CrossRef Google Scholar

Thakore, J.H.Mann, J.N.Vlahos, I.Martin, A.Reznek, R.H.Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes 2002;26:137–141CrossRef Google Scholar PubMed

Tiihonen, J.Wahlbeck, K.Lönnqvist, J.Klaukka, T.Ioannidis, J.P.Volavka, J.et al.Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006;333(7561):224 [Epub 2006 Jul 6]CrossRef Google Scholar

The international expert committee International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32:1327–L1334 doi: 10.2337/dc09-9033.CrossRef Google Scholar

Tschoner, A.Engl, J.Laimer, M.S.Rettenbacher, M.Fleischhacker, W.et al.Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007;61(8):1356–1370CrossRef Google Scholar PubMed

Tuomilehto, J.Lindström, J.Eriksson, J.G.Valle, T.T.Hämäläinen, H.et al.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343–1350CrossRef Google Scholar PubMed

Ussher, M.H.Taylor, A.Faulkner, G.Exercise interventions for smoking cessation. Cochrane Database Syst Rev 2008;4:CD002295Google Scholar

van Winkel, R.De Hert, M.Van Eyck, D.Hanssens, L.Wampers, M.Scheen, A.et al.Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry 2006;67(10):1493–1500CrossRef Google Scholar PubMed

van Winkel, R.De Hert, M.Wampers, M.Van Eyck, D.Hanssens, L.Scheen, A.et al.Major changes in glucose metabolism including new-onset diabetes within 3 months after initiation or switch of atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008;69:472–479CrossRef Google Scholar PubMed

van Winkel, R.De Hert, M.Van Eyck, D.Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008;10:342–348CrossRef Google Scholar

van Winkel, R.van Os, J.Celic, I.Van Eyck, D.Wampers, M.Scheen, A.et al.Psychiatric diagnosis as an independent risk factor for metabolic disturbance. Results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008;69(8):1319–1327CrossRef Google Scholar PubMed

Waterreus, A.J.Laugharne, J.D.Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Med J Aust 2009;190(4):185–189CrossRef Google Scholar PubMed

World Health Organisation: Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia– Report of a WHO/IDF Consultation, 2006.Google Scholar

Wu, R.R.Zhao, J.P.Liu, Z.N.Zhai, J.G.Guo, X.F.Guo, W.B.et al.Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006;186(4):572–578CrossRef Google Scholar PubMed

Wu, R.R.Zhao, J.P.Jin, H.Shao, P.Fang, M.S.Guo, X.F.et al.Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008;299(2):185–193CrossRef Google Scholar PubMed

Zimmermann, U.Kraus, T.Himmerich, H.Schuld, A.Pollmächer, T.Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003;37:193–220CrossRef Google Scholar PubMed